» Articles » PMID: 31193863

Cost-effectiveness of HIV Prevention Interventions in Sub-Saharan Africa: A Systematic Review

Overview
Specialty General Medicine
Date 2019 Jun 14
PMID 31193863
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sub-Saharan Africa carries the highest HIV burden globally. It is important to understand how interventions cost-effectively fit within guidelines and implementation plans, especially in low- and middle-income settings. We reviewed the evidence from economic evaluations of HIV prevention interventions in sub-Saharan Africa to help inform the allocation of limited resources.

Methods: We searched PubMed, Web of Science, Econ-Lit, Embase, and African Index Medicus. We included studies published between January 2009 and December 2018 reporting cost-effectiveness estimates of HIV prevention interventions. We extracted health outcomes and cost-effectiveness ratios (CERs) and evaluated study quality using the CHEERS checklist.

Findings: 60 studies met the full inclusion criteria. Prevention of mother-to-child transmission interventions had the lowest median CERs ($1144/HIV infection averted and $191/DALY averted), while pre-exposure prophylaxis interventions had the highest ($13,267/HIA and $799/DALY averted). Structural interventions (partner notification, cash transfer programs) have similar CERs ($3576/HIA and $392/DALY averted) to male circumcision ($2965/HIA) and were more favourable to treatment-as-prevention interventions ($7903/HIA and $890/DALY averted). Most interventions showed increased cost-effectiveness when prioritizing specific target groups based on age and risk.

Interpretation: The presented cost-effectiveness information can aid policy makers and other stakeholders as they develop guidelines and programming for HIV prevention plans in resource-constrained settings.

Citing Articles

Value is Gendered: The Need for Sex and Gender Considerations in Health Economic Evaluations.

Mchenga M, Vijayasingham L, RamPrakash R, Remme M Appl Health Econ Health Policy. 2024; 23(2):171-181.

PMID: 39666245 PMC: 11811431. DOI: 10.1007/s40258-024-00930-z.


Costs and resource distribution of direct services for HIV in Uganda.

Ekirapa E, Jordan M, Nong T, Marton T, Balidawa H, Ssempala R BMJ Open. 2024; 14(10):e082062.

PMID: 39384227 PMC: 11474907. DOI: 10.1136/bmjopen-2023-082062.


Developing a framework for understanding policy decision-making behaviors in the transition of an HIV prevention program towards sustainability: a case study from Zambia's voluntary medical male circumcision program.

Gantayat N, Baer J, Gangaramany A, Kretschmer S, Surana R, Samona A Gates Open Res. 2024; 8:18.

PMID: 39319309 PMC: 11421490. DOI: 10.12688/gatesopenres.15189.2.


Costs of HIV testing services in sub-Saharan Africa: a systematic literature review.

Ahmed N, Ong J, McGee K, dElbee M, Johnson C, Cambiano V BMC Infect Dis. 2024; 22(Suppl 1):980.

PMID: 39192180 PMC: 11348535. DOI: 10.1186/s12879-024-09770-7.


Asymptomatic Rectal Bacterial Pathogens Show Large Prospective Relationships With HIV Incidence in a Cohort of Young Sexual and Gender Minorities: Implications for STI Screening and HIV Prevention.

Baiers R, Ryan D, Clifford A, Munson E, DAquila R, Newcomb M Open Forum Infect Dis. 2024; 11(8):ofae444.

PMID: 39183815 PMC: 11342390. DOI: 10.1093/ofid/ofae444.


References
1.
Bertram M, Lauer J, de Joncheere K, Edejer T, Hutubessy R, Kieny M . Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016; 94(12):925-930. PMC: 5153921. DOI: 10.2471/BLT.15.164418. View

2.
Terris-Prestholt F, Foss A, Cox A, Heise L, Meyer-Rath G, Delany-Moretlwe S . Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. BMC Infect Dis. 2014; 14:14. PMC: 3899035. DOI: 10.1186/1471-2334-14-14. View

3.
Remme M, Vassall A, Lutz B, Luna J, Watts C . Financing structural interventions: going beyond HIV-only value for money assessments. AIDS. 2014; 28(3):425-34. DOI: 10.1097/QAD.0000000000000076. View

4.
Glaubius R, Hood G, Penrose K, Parikh U, Mellors J, Bendavid E . Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa. Clin Infect Dis. 2016; 63(4):539-47. PMC: 4967601. DOI: 10.1093/cid/ciw321. View

5.
McGillen J, Anderson S, Hallett T . PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa. J Int AIDS Soc. 2016; 19(7(Suppl 6)):21104. PMC: 5071752. DOI: 10.7448/IAS.19.7.21104. View